About Waters (NYSE:WAT)
Waters Corporation is an analytical instrument manufacturer. The Company operates through two segments: Waters and TA. It designs, manufactures, sells and services high performance liquid chromatography (HPLC), ultra performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and post-warranty service plans. It also designs, manufactures, sells and services thermal analysis, rheometry and calorimetry instruments through its TA product line. It is also a developer and supplier of software-based products that interface with the Company's instruments, as well as other suppliers' instruments. Its LC and LC-MS instruments are utilized in a range of industries to detect, identify, monitor and measure the chemical, physical and biological composition of materials, and to purify a range of compounds.
Industry, Sector and Symbol
Industry Advanced Medical Equipment & Technology
Sub-IndustryLife Sciences Tools & Services
Trailing P/E Ratio30.8171091445428
Forward P/E Ratio28.16
Sales & Book Value
Annual Sales$2.17 billion
Price / Sales7.67
Cash Flow$7.86 per share
Price / Cash26.59
Book Value$28.57 per share
Price / Book7.31
Net Income$521.50 million
Return on Equity23.61%
Return on Assets11.84%
Waters (NYSE:WAT) Frequently Asked Questions
What is Waters' stock symbol?
Waters trades on the New York Stock Exchange (NYSE) under the ticker symbol "WAT."
How will Waters' stock buyback program work?
Waters announced that its board has authorized a stock repurchase plan on Sunday, June 4th 2017, which permits the company to repurchase $1,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 7.3% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company's board of directors believes its stock is undervalued.
How were Waters' earnings last quarter?
Waters Co. (NYSE:WAT) released its quarterly earnings results on Tuesday, October, 24th. The medical instruments supplier reported $1.77 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.74 by $0.03. The medical instruments supplier earned $565.58 million during the quarter, compared to the consensus estimate of $555.25 million. Waters had a return on equity of 23.61% and a net margin of 24.34%. Waters's revenue was up 7.4% on a year-over-year basis. During the same period last year, the company earned $1.57 earnings per share. View Waters' Earnings History.
When will Waters make its next earnings announcement?
Where is Waters' stock going? Where will Waters' stock price be in 2018?
15 analysts have issued 12-month price targets for Waters' stock. Their forecasts range from $175.00 to $230.00. On average, they anticipate Waters' stock price to reach $195.93 in the next year. View Analyst Ratings for Waters.
What are Wall Street analysts saying about Waters stock?
Here are some recent quotes from research analysts about Waters stock:
- 1. According to Zacks Investment Research, "Waters Corp. has an excellent earnings history, having surpassed estimates in each of the trailing four quarters. Going forward, the company believes that stable demand from pharmaceutical business, steady recurring revenues, strength in Asia and modest recovery in industrial markets will accelerate its momentum. Based on these dynamics, the company is expecting strong mid-single-digit constant currency sales increase. Even the government and academic markets have returned to the growth track after sustained weakness. However, the company’s growth will likely be hindered by contracting demand in the Americas. Waters Corp. also intends to increase its spending on research and development in the coming quarters, which, although beneficial in the long run, will push expenses higher and hurt immediate profits. Further, shares of Waters Corp. have underperformed the industry’s average return over past six months." (1/6/2018)
- 2. Deutsche Bank AG analysts commented, "needle-movers" that could generate growth for the next year.Finally, the increase in Leonard's price target merely reflects an expansion in the peer multiple and a six-month roll-forward of his valuation period.Related Links:Benzinga's Top Upgrades, Downgrades For July 10, 2017Pressure Biosciences CEO On Its Beaten Down Stock: 'We Can Now Begin To Focus On The Area That Is Most Important'______Image Credit: By NASA [Public domain], via Wikimedia Commons Posted-In: Dan Leonard Deutsche Bank ToolsAnalyst Color Downgrades Price Target Analyst Ratings Tech Best of Benzinga © 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Related Articles (WAT) Benzinga's Top Upgrades, Downgrades For July 10, 2017 View Comments and Join the Discussion! View the discussion thread. document.write('') Newsletter & Alerts